Novartis Triple Combo Enerzair Gets EU OK For Asthma
Nudges Ahead Of GSK's Trelegy in Europe
The Swiss company's asthma triplet is now approved in Europe and Japan but Enerzair is well behind GSK's rival LABA/LAMA/ICS in the US where Novartis's product has not even been submitted yet.
You may also be interested in...
The Japanese firm with R&D operations in the UK is conducting a search to find "a potentially transformative acquisition," helped by a significant financing round.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, two world-first nods for the country’s second HIF-PH inhibitors and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.
The company filed an sNDA with the US FDA for the triple combination, hoping to expand its current COPD indication to also include asthma.